Shareholder Alert: Ademi LLP investigates whether Cyclerion Therapeutics Inc. is obtaining a Fair Price for Public Shareholders
MILWAUKEE, April 1, 2026 /PRNewswire/ — Ademi LLP is investigating Cyclerion (NASDAQ: CYCN) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with Korsana.
Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you.
In the transaction, pre-merger Cyclerion shareholders are expected to own approximately 1.5% of the combined company, while pre-merger Korsana stockholders will own approximately 98.5%. Cyclerion insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for Cyclerion by imposing a significant penalty if Cyclerion accepts a competing bid. We are investigating the conduct of the Cyclerion board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
Contacts
Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-cyclerion-therapeutics-inc-is-obtaining-a-fair-price-for-public-shareholders-302732000.html
SOURCE Ademi LLP
Disclaimer: The above press release comes to you under an arrangement with PR Newswire. NYnewscast.com takes no editorial responsibility for the same.
